Applications of Sequential Pathogenesis Technology SLIL has obtained an exclusive license to the Sequential Pathogenesis Model from the University of California, San Francisco. This new disease model focuses on the recently discovered role of macrophages in disease and is particularly applicable to cancers. The model will help target our anti-cancer research efforts, and in the longer term, could have far-reaching diagnostic and prognostic applications for a variety of diseases. The possible therapeutic, diagnostic (and prognostic) applications of this model are discussed below. Drug Screening: SLIL is developing the capability to screen compounds to rapidly identify Candidate Drugs which will selectively inhibit or kill proliferating macrophages (ProMacs™). Patient Pre-Selection for Clinical Trials: Patients enrolling in clinical trials could be pre-screened. Patients whose blood contains ProMacs, who are most likely to benefit from treatment targeted against these macrophages could be selected for trials. Diagnostic and Prognostic Screens: SLIL could develop and utilize screens to identify patients at risk for developing diseases associated with ProMacs. Opportunities associated with the discovery of additional new retroviruses include licensing select viruses to pharmaceutical companies for vaccine development and as new therapeutic targets for drug discovery, as well as for diagnostics (including blood transfusion screening). As disease-specific ProMacs are detected, characterized and made diagnostically practical, they may offer new indicators of disease, perhaps at a stage well before clinical symptoms emerge.